Conditions: Vitreous Hemorrhage
Keywords: Proliferative Diabetic Retinopathy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 12
Healthy volunteers: no

Brief summary:
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.

Detailed description:
Patients who need Pars Plana Vitrectomy surgery, and agree to participate in this study will receive an injection of 2.0mg aflibercept 4 to 6 days before Vitrectomy surgery. Half of these patients will be randomized to receive another injection of 2.0mg aflibercept immediately after their surgery. Postoperative patient visits in this study will be at 1 day, and at weeks 1, 4, 16 and 24, and at any other times as deemed necessary by the Investigator.

Arms:
arm 1: Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection. arm 2: Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.

Interventions: intervention 1: Intravitreal Aflibercept Injection intervention 2: Standard Vitrectomy
Intervention descriptions: intervention 1: One time 2.0mg aflibercept injection, following pars plana vitrectomy. intervention 2: Surgical intervention

Protocol document: